Featured publications
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
November 2, 2023 | The New England Journal of Medicine
Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development
April 5, 2023 | Frontiers in Molecular Biosciences
Quantifying the nativeness of antibody sequences using long short-term memory networks
December 31, 2019 | Protein Engineering, Design, and Selection
State-of-Art Therapeutics in IgA Nephropathy
August 30, 2024 | Indian Journal of Nephrology
Minimal Change Disease and FSGS Are a Spectrum of a Single Disease within Immune-Mediated Nephrotic Syndrome
August 5, 2024 | Kidney360
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group
June 3, 2024 | Clinical Journal of the American Society of Nephrology
A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models
March 1, 2024 | The Journal of Clinical Investigation
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence
November 4, 2023 | Journal of Clinical Medicine
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
November 2, 2023 | The New England Journal of Medicine
Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections
September 19, 2023 | PLOS Pathogens
Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants
August 11, 2023 | Clinical Development in Drug Pharmacology
Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review
August 4, 2023 | Kidney360
The incidence and prevalence of IgA nephropathy in Europe
May 8, 2023 | Nephrology Dialysis Transplantation
- 1
- 2
- 3
- …
- 6
- Next Page »